Radzikowska Elżbieta, Roży Adriana, Jagus Paulina, Polubiec-Kownacka Małgorzata, Wiatr Elżbieta, Chorostowska-Wynimko Joanna, Roszkowski-Śliż Kazimierz
Third Department of Lung Disease, National Tuberculosis and Lung Disease Research Institute, Warszawa, Poland.
Laboratory of Molecular Diagnostics and Immunology, National Tuberculosis and Lung Disease Research Institute, Warszawa, Poland.
Adv Clin Exp Med. 2016 Sep-Oct;25(5):871-878. doi: 10.17219/acem/61953.
Inflammatory cytokines are involved in the development of cryptogenic organizing pneumonia (COP). It has been shown that macrolides inhibit cytokine production in the alveolar macrophages of COP patients.
The aim of the study was to assess the concentrations of interleukin 1β (IL-1β), IL-6, IL-8 and transforming growth factor β (TGF-β) in serum and in bronchoalveolar lavage fluid (BAL-f) in COP patients treated with clarithromycin (CAM).
The study involved 26 patients (18 women and 8 men, mean age 56.46 ± 8.83 years) with biopsy-proven COP. After being treated with CAM, a complete recovery was achieved in 22 patients, while four patients did not respond to the treatment. The ELISA method was used to measure the serum and BAL-f concentrations of IL-1β, IL-6, IL-8 and TGF-β.
Before treatment, the serum IL-1β1, IL-6, IL-8 and TGF-β1 concentrations were similar in responders and non-responders. Significant decreases in serum concentrations of IL-6 (8.98 ± 13.26 pg/mL vs. 3.1 ± 6.95 pg/mL; p = 0.005), IL-8 (20.14 ± 25.72 pg/mL vs. 10.14 ± 6.8 pg/mL; p = 0.007) and TGF-β1 (37.89 ± 12.49 ng/mL vs. 26.49 ± 12.45 ng/mL; p = 0.001) were found after treatment, as well as a significant decrease in the BAL-f concentration of IL-6 (30.56 ± 56.78 pg/mL vs. 4.53 ± 5.84 pg/mL; p = 0.036). Clarithromycin treatment resulted in a significantly lower mean value of serum IL-6 responders than non-responders.
In COP patients, response to clarithromycin treatment was associated with decreases in serum concentrations of IL-6, IL-8 and TGF-β, and of rations, and of the BAL-f concentration of IL-6.
炎症细胞因子参与隐源性机化性肺炎（COP）的发病过程。已有研究表明，大环内酯类药物可抑制COP患者肺泡巨噬细胞中细胞因子的产生。
本研究旨在评估克拉霉素（CAM）治疗的COP患者血清及支气管肺泡灌洗液（BAL-f）中白细胞介素1β（IL-1β）、IL-6、IL-8和转化生长因子β（TGF-β）的浓度。
本研究纳入26例经活检证实为COP的患者（18例女性，8例男性，平均年龄56.46±8.83岁）。接受CAM治疗后，22例患者完全康复，4例患者治疗无效。采用酶联免疫吸附测定（ELISA）法检测血清及BAL-f中IL-1β、IL-6、IL-8和TGF-β的浓度。
治疗前，反应者和无反应者的血清IL-1β1、IL-6、IL-8和TGF-β1浓度相似。治疗后，血清IL-6（8.98±13.26 pg/mL对3.1±6.95 pg/mL；p = 0.005）、IL-8（20.14±25.72 pg/mL对10.14±6.8 pg/mL；p = 0.007）和TGF-β1（37.89±12.49 ng/mL对26.49±12.45 ng/mL；p = 0.001）浓度显著降低，BAL-f中IL-6浓度也显著降低（30.56±56.78 pg/mL对4.53±5.84 pg/mL；p = 0.036）。克拉霉素治疗后，反应者血清IL-6的平均值显著低于无反应者。
在COP患者中，对克拉霉素治疗的反应与血清IL-6、IL-8和TGF-β浓度降低以及BAL-f中IL-6浓度降低有关。
